Posted on NaviNet Plan Central page 2-1-2017 FIVE CANCER TYPES TO BE ADDED TO MEDICAL ONCOLOGY PATHWAYS PROGRAM 4/1/17 Beginning April 1, 2017, the Highmark Medical Oncology Management Pathways Program will expand to include five additional cancer types. Providers can expect to see the new content in the Clear Value PlusSM decision support tool starting April 1, 2017. All decisions made on or after April 1, 2017, for the new cancers will be calculated in the practice’s concordance score. All other program components remain the same. The following cancer types will be added to the Pathways Program starting April 1, 2017: • Bladder cancer • Esophageal and esophageal junction cancers • Gastric cancer • Kidney cancer • Myelodysplastic syndrome Benefits of this Pathways Program expansion include: • Access to clinical decision support for five additional cancers • Ability to provide high-quality, cost-effective care to a greater number of Highmark and non- Highmark members • Increased opportunity to improve or maintain high concordance by selecting Value Pathways for the new cancers Effective April 1, 2017, the complete list of cancer types in the Highmark Medical Oncology Management Pathways Program will be as follows: • Breast cancer • Chronic myelogenous leukemia (CML) • Colon cancer • Fallopian tube cancer • Head and neck cancer: (oropharyngeal, laryngeal, hypopharyngeal) • Hodgkin’s lymphoma • Melanoma • Multiple myeloma • Non-Hodgkin's lymphomas: (DLBCL, Follicular, CLL, SLL, Mantle Cell) • Ovarian cancer • Pancreatic adenocarcinoma • Primary peritoneal cancer • Prostate cancer • Rectal cancer (continued) • Small cell lung cancer • Non-small cell lung cancer • Esophageal and esophagogastric junction cancers (starting 4-1-17) • Gastric cancer (starting 4-1-17) • Kidney cancer (starting 4-1-17) • Myelodysplastic syndrome (starting 4-1-17) • Bladder cancer (starting 4-1-17) .